ABSTRACT
This chapter describes trade name, classification, approved indications for psychological disorders, available dosage forms, storage, and compatibility, usual dosage and administration, relative contraindications, and clinically significant drug interactions of Dexfenfluramine. Safety and efficacy of dexfenfluramine pharmacotherapy for women who are pregnant have not been established. Avoid prescribing dexfenfluramine pharmacotherapy to women who are pregnant. Concurrent dexfenfluramine and antihypertensive pharmacotherapy may require an adjustment in the dosage of the antihypertensive. Fatal dexfenfluramine overdosages have occurred but reportedly are relatively rare. Signs and symptoms of dexfenfluramine overdosage include abnormal dilation of the pupils, agitation, drowsiness, nausea, sweating , and vomiting. Dexfenfluramine overdosage requires emergency symptomatic medical support of body systems with attention to increasing dexfenfluramine elimination. Safety and efficacy of dexfenfluramine pharmacotherapy beyond twelve months duration have not yet been determined. Safety and efficacy of dexfenfluramine pharmacotherapy for women who are breast-feeding and their neonates and infants have not been established.
